{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:27:43Z","timestamp":1773678463200,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SE2373\/1-2"],"award-info":[{"award-number":["SE2373\/1-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40272-026-00737-6","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T08:09:12Z","timestamp":1771142952000},"page":"187-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute Phase Reaction After First Neridronate Infusion in Children with Osteogenesis Imperfecta: An Analysis Based on Questionnaire Data from 65 Patients"],"prefix":"10.1007","volume":"28","author":[{"given":"Felicitas","family":"Haselwarter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0195-9428","authenticated-orcid":false,"given":"Stefanie","family":"Stasek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina Eva","family":"Rehberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Hoyer-Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Reincke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"N\u00fcsken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Semler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirko","family":"Rehberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"737_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002010.pub5","author":"TC Jeffery","year":"2023","unstructured":"Jeffery TC, Chang AB, Conwell LS. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2023. https:\/\/doi.org\/10.1002\/14651858.CD002010.pub5.","journal-title":"Cochrane Database Syst Rev"},{"key":"737_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004956.pub3","author":"L Corral-Gudino","year":"2017","unstructured":"Corral-Gudino L, Tan AJ, del Pino-Montes J, Ralston SH. Bisphosphonates for Paget\u2019s disease of bone in adults. Cochrane Database Syst Rev. 2017. https:\/\/doi.org\/10.1002\/14651858.CD004956.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"737_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947\u201352. https:\/\/doi.org\/10.1056\/NEJM199810013391402.","journal-title":"N Engl J Med"},{"key":"737_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1399-3046.2004.00191.x","volume":"8","author":"AA El-Husseini","year":"2004","unstructured":"El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA, Ghoneim MA. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatr Transplant. 2004;8:357\u201361. https:\/\/doi.org\/10.1111\/j.1399-3046.2004.00191.x.","journal-title":"Pediatr Transplant"},{"key":"737_CR5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/j.1442-200X.2010.03174.x","volume":"52","author":"AM Sbrocchi","year":"2010","unstructured":"Sbrocchi AM, Forget S, Laforte D, Azouz EM, Rodd C. Zoledronic acid for the treatment of osteopenia in pediatric Crohn\u2019s disease. Pediatr Int. 2010;52:754\u201361. https:\/\/doi.org\/10.1111\/j.1442-200X.2010.03174.x.","journal-title":"Pediatr Int"},{"issue":"Suppl 6","key":"737_CR6","first-page":"33","volume":"9","author":"L Lepore","year":"1991","unstructured":"Lepore L, Pennesi M, Barbi E, Pozzi R. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol. 1991;9(Suppl 6):33\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"737_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jpeds.2007.08.047","volume":"152","author":"PJ Simm","year":"2008","unstructured":"Simm PJ, Allen RC, Zacharin MR. Bisphosphonate treatment in chronic recurrent multifocal osteomyelitis. J Pediatr. 2008;152:571\u20135. https:\/\/doi.org\/10.1016\/j.jpeds.2007.08.047.","journal-title":"J Pediatr"},{"key":"737_CR8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00431-010-1188-5","volume":"169","author":"T Hospach","year":"2010","unstructured":"Hospach T, Langendoerfer M, von Kalle T, Maier J, Dannecker GE. Spinal involvement in chronic recurrent multifocal osteomyelitis (CRMO) in childhood and effect of pamidronate. Eur J Pediatr. 2010;169:1105\u201311. https:\/\/doi.org\/10.1007\/s00431-010-1188-5.","journal-title":"Eur J Pediatr"},{"key":"737_CR9","first-page":"707","volume":"35","author":"H Gleeson","year":"2008","unstructured":"Gleeson H, Wiltshire E, Briody J, Hall J, Chaitow J, Sillence D, et al. Childhood chronic recurrent multifocal osteomyelitis: pamidronate therapy decreases pain and improves vertebral shape. J Rheumatol. 2008;35:707\u201312.","journal-title":"J Rheumatol"},{"key":"737_CR10","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","volume":"387","author":"A Forlino","year":"2016","unstructured":"Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016;387:1657\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(15)00728-X.","journal-title":"Lancet"},{"key":"737_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.52","volume":"3","author":"JC Marini","year":"2017","unstructured":"Marini JC, Forlino A, B\u00e4chinger HP, Bishop NJ, Byers PH, De Paepe A, et al. Osteogenesis imperfecta. Nat Rev Dis Prim. 2017;3:1\u201319. https:\/\/doi.org\/10.1038\/nrdp.2017.52.","journal-title":"Nat Rev Dis Prim"},{"key":"737_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrendo.2011.81","volume":"7","author":"A Forlino","year":"2011","unstructured":"Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011;7:540\u201357. https:\/\/doi.org\/10.1038\/nrendo.2011.81.","journal-title":"Nat Rev Endocrinol"},{"key":"737_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.bone.2017.07.004","volume":"103","author":"L Idolazzi","year":"2017","unstructured":"Idolazzi L, Fassio A, Viapiana O, Rossini M, Adami G, Bertoldo F, et al. Treatment with neridronate in children and adolescents with osteogenesis imperfecta: data from open-label, not controlled, three-year Italian study. Bone. 2017;103:144\u20139. https:\/\/doi.org\/10.1016\/j.bone.2017.07.004.","journal-title":"Bone"},{"key":"737_CR14","unstructured":"Study to evaluate efficacy and safety of romosozumab compared with bisphosphonates in children and adolescents with osteogenesis imperfecta. n.d. https:\/\/clinicaltrials.gov\/study\/NCT05972551. Accessed 7 Oct 2024."},{"key":"737_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.573976","author":"ZR D\u00f6m\u00f6t\u00f6r","year":"2020","unstructured":"D\u00f6m\u00f6t\u00f6r ZR, V\u00f6rhendi N, Han\u00e1k L, Hegyi P, Kiss S, Csiki E, et al. Oral treatment with bisphosphonates of osteoporosis does not increase the risk of severe gastrointestinal side effects: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2020. https:\/\/doi.org\/10.3389\/fendo.2020.573976.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"737_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02728-z","volume":"18","author":"S Wehrli","year":"2023","unstructured":"Wehrli S, Rohrbach M, Landolt MA. Quality of life of pediatric and adult individuals with osteogenesis imperfecta: a meta-analysis. Orphanet J Rare Dis. 2023;18(1):123. https:\/\/doi.org\/10.1186\/s13023-023-02728-z.","journal-title":"Orphanet J Rare Dis."},{"key":"737_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/BF02556671","volume":"41","author":"S Adami","year":"1987","unstructured":"Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int. 1987;41:326\u201331. https:\/\/doi.org\/10.1007\/BF02556671.","journal-title":"Calcif Tissue Int"},{"key":"737_CR18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1136\/archdischild-2023-326287","volume":"109","author":"S Nayak","year":"2024","unstructured":"Nayak S, Rayner L, Mughal Z, McKinney G, Mason A, Wong SC, et al. Severity of acute phase reaction in children receiving the first dose of zoledronic acid and the impact of the underlying condition: a cross-sectional study. Arch Dis Child. 2024;109:849\u201353. https:\/\/doi.org\/10.1136\/archdischild-2023-326287.","journal-title":"Arch Dis Child"},{"key":"737_CR19","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1210\/jc.2005-0057","volume":"90","author":"SM Ott","year":"2005","unstructured":"Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005;90:1897\u20139. https:\/\/doi.org\/10.1210\/jc.2005-0057.","journal-title":"J Clin Endocrinol Metab"},{"key":"737_CR20","doi-asserted-by":"publisher","first-page":"093","DOI":"10.1055\/s-0039-1700972","volume":"09","author":"E Maines","year":"2020","unstructured":"Maines E, Tadiotto E, Morandi G, Fedrizzi M, Gaudino R, Cavarzere P, et al. Hypocalcemia following Neridronate administration in pediatric patients with osteogenesis imperfecta: a prospective observational study. J Pediatr Genet. 2020;09:093\u2013100. https:\/\/doi.org\/10.1055\/s-0039-1700972.","journal-title":"J Pediatr Genet"},{"key":"737_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03126-9","volume":"19","author":"I Westerheim","year":"2024","unstructured":"Westerheim I, Hart T, van Welzenis T, Wekre LL, Semler O, Raggio C, et al. The IMPACT survey: a mixed methods study to understand the experience of children, adolescents and adults with osteogenesis imperfecta and their caregivers. Orphanet J Rare Dis. 2024;19:128. https:\/\/doi.org\/10.1186\/s13023-024-03126-9.","journal-title":"Orphanet J Rare Dis"},{"key":"737_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2021.07.393","volume":"102","author":"MR Celin","year":"2021","unstructured":"Celin MR, Kruger K, Caudill A, Murali CN, Nagamani S, Smith PA, et al. Multicenter study of pain in osteogenesis imperfecta. Arch Phys Med Rehabil. 2021;102:e2. https:\/\/doi.org\/10.1016\/j.apmr.2021.07.393.","journal-title":"Arch Phys Med Rehabil"},{"key":"737_CR23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.rehab.2011.07.002","volume":"54","author":"S Wagner","year":"2011","unstructured":"Wagner S, Poirot I, Vuillerot C, Berard C. Tolerance and effectiveness on pain control of Pamidronate\u00ae intravenous infusions in children with neuromuscular disorders. Ann Phys Rehabil Med. 2011;54:348\u201358. https:\/\/doi.org\/10.1016\/j.rehab.2011.07.002.","journal-title":"Ann Phys Rehabil Med"},{"key":"737_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/1049909118793114","volume":"36","author":"DL Anghelescu","year":"2019","unstructured":"Anghelescu DL, Pankayatselvan V, Nguyen R, Ward D, Wu J, Wu H, et al. Bisphosphonate use in pediatric oncology for pain management. Am J Hospice Palliat Med. 2019;36:138\u201342. https:\/\/doi.org\/10.1177\/1049909118793114.","journal-title":"Am J Hospice Palliat Med"},{"key":"737_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000381713","volume":"84","author":"EBG Rijks","year":"2015","unstructured":"Rijks EBG, Bongers BC, Vlemmix MJG, Boot AM, van Dijk ATH, Sakkers RJB, et al. Efficacy and safety of bisphosphonate therapy in children with osteogenesis imperfecta: a systematic review. Horm Res Paediatr. 2015;84:26\u201342. https:\/\/doi.org\/10.1159\/000381713.","journal-title":"Horm Res Paediatr"},{"key":"737_CR26","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jbspin.2019.06.005","volume":"86","author":"J Su\u0142ko","year":"2019","unstructured":"Su\u0142ko J, Ebisz M, Bie\u0144 S, B\u0142a\u017ckiewicz M, Jurczyk M, Namy\u015blak M. Treatment of chronic recurrent multifocal osteomyelitis with bisphosphonates in children. Jt Bone Spine. 2019;86:783\u20138. https:\/\/doi.org\/10.1016\/j.jbspin.2019.06.005.","journal-title":"Jt Bone Spine"},{"issue":"1","key":"737_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","volume":"18","author":"S Adami","year":"2003","unstructured":"Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tat\u00f2 L. Intravenous neridronate in adults with osteogenesis imperfecta. JBone Miner Res. 2003;18(1):126\u201330. https:\/\/doi.org\/10.1359\/jbmr.2003.18.1.126.","journal-title":"JBone Miner Res."},{"key":"737_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.bone.2019.01.003","volume":"121","author":"N Nasomyont","year":"2019","unstructured":"Nasomyont N, Hornung LN, Gordon CM, Wasserman H. Outcomes following intravenous bisphosphonate infusion in pediatric patients: a 7-year retrospective chart review. Bone. 2019;121:60\u20137. https:\/\/doi.org\/10.1016\/j.bone.2019.01.003.","journal-title":"Bone"},{"key":"737_CR29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/1078155207080806","volume":"13","author":"K Olson","year":"2007","unstructured":"Olson K, Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract. 2007;13:223\u20139. https:\/\/doi.org\/10.1177\/1078155207080806.","journal-title":"J Oncol Pharm Pract"},{"key":"737_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/8756-3282(95)00448-3","volume":"18","author":"A Sauty","year":"1996","unstructured":"Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, et al. Interleukin-6 and tumor necrosis factor \u03b1 levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone. 1996;18:133\u20139. https:\/\/doi.org\/10.1016\/8756-3282(95)00448-3.","journal-title":"Bone"},{"key":"737_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","volume":"139","author":"RE Hewitt","year":"2004","unstructured":"Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2004;139:101\u201311. https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02665.x.","journal-title":"Clin Exp Immunol"},{"key":"737_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.bone.2007.05.002","volume":"41","author":"CF Munns","year":"2007","unstructured":"Munns CF, Rajab MH, Hong J, Briody J, H\u00f6gler W, McQuade M, et al. Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone. 2007;41:366\u201370. https:\/\/doi.org\/10.1016\/j.bone.2007.05.002.","journal-title":"Bone"},{"key":"737_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0928-0987(98)00065-7","volume":"8","author":"N Makkonen","year":"1999","unstructured":"Makkonen N, Salminen A, Rogers MJ, Frith JC, Urtti A, Azhayeva E, et al. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur J Pharm Sci. 1999;8:109\u201318. https:\/\/doi.org\/10.1016\/S0928-0987(98)00065-7.","journal-title":"Eur J Pharm Sci"},{"key":"737_CR34","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jpeds.2004.06.066","volume":"145","author":"W H\u00f6gler","year":"2004","unstructured":"H\u00f6gler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr. 2004;145:701\u20134. https:\/\/doi.org\/10.1016\/j.jpeds.2004.06.066.","journal-title":"J Pediatr"},{"key":"737_CR35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1542\/peds.2011-3059","volume":"130","author":"JD McNally","year":"2012","unstructured":"McNally JD, Menon K, Chakraborty P, Fisher L, Williams KA, Al-Dirbashi OY, et al. The association of vitamin D status with pediatric critical illness. Pediatrics. 2012;130:429\u201336. https:\/\/doi.org\/10.1542\/peds.2011-3059.","journal-title":"Pediatrics"},{"key":"737_CR36","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/sj.bjp.0702367","volume":"126","author":"Y Endo","year":"1999","unstructured":"Endo Y, Shibazaki M, Yamaguchi K, Nakamura M, Kosugi H. Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Br J Pharmacol. 1999;126:903\u201310. https:\/\/doi.org\/10.1038\/sj.bjp.0702367.","journal-title":"Br J Pharmacol"},{"key":"737_CR37","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00198-010-1448-2","volume":"22","author":"SL Silverman","year":"2011","unstructured":"Silverman SL, Kriegman A, Goncalves J, Kianifard F, Carlson T, Leary E. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporos Int. 2011;22:2337\u201345. https:\/\/doi.org\/10.1007\/s00198-010-1448-2.","journal-title":"Osteoporos Int"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00737-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00737-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00737-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:13:14Z","timestamp":1773673994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00737-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["737"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00737-6","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee (approval number: 15-149).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}},{"value":"Informed consent was obtained from all participants or their guardians.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data supporting the findings of this study are available upon reasonable request from the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"FH (writing\u2014original draft, visualization, writing\u2014review and editing) and SS (writing\u2014original draft, visualization, formal analysis, writing\u2014review and editing) both contributed equally as co-first authors. KER: investigation, writing\u2014review and editing, formal analysis; HH-K: conceptualization, methodology, resources, writing\u2014review and editing, project administration; OS: conceptualization, supervision, methodology, resources, writing\u2014review and editing; SR: writing\u2014review and editing; EN: writing\u2014review and editing; MR: conceptualization, methodology, supervision, writing\u2014review and editing. All authors have read and agreed to the published version of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}